Hepsera showing greater choice of therapeutic options

Published: 2004-06-04 06:57:00

Updated: 2004-06-04 06:57:00

Local studies have shown that GSK's novel nucleotide analogue Hepsera (adefovir dipivoxil; ADV), which was launched in February in Korea, is effective in a broad range of patients with chronic hepatitis B (CHB), including those with lamivudine-resistant HBV, HBV co-infection and decompensated liv...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK